[비즈한국] HLB028300 has begun revising its strategy to protect 'Rivoceranib,' the core pipeline responsible for most of the group's corporate value. Amid the dual pressures of delayed U.S. approval and approaching patent expiration, the company is attracting attention by moving away from its previous reliance on Chinese partners for combination therapy development and seeking a breakthrough in new combination strategies and patent extensions through collaborations with domestic biotech firms.
HLB is expanding collaborations with domestic companies as part of a patent extension strategy for the targeted anticancer drug Rivoceranib, which is facing patent expiration. Photo = Reporter Choi Young-chan
